You are here
Scientific Advisory Boards
Karoly Nikolich, Ph.D., Chairman of the Scientific Advisory Board
Karoly Nikolich has been director and SAB member of several biotech companies. He served as CEO of Amnestix, Inc, between 2007 and 2010; during this time he was also US partner and advisor of dievini investments. Earlier, he was executive director of the Neuroscience Institute at Stanford University. Karoly co-founded several biotech companies, including AGY Therapeutics with Bob Swanson in 1998. He started his career in the biotech industry as a scientist at Genentech during the early 1980s where he initiated and built the company’s first neuroscience research program. Later, he was VP Research at Lynx Therapeutics (acquired by Solexa/Illumina). Karoly is currently Consulting Professor at Stanford University Medical School and was formerly Adjunct Professor at the University of Southern California. As a scientist he co-authored 130 publications. He has been an investment advisor to several public and private venture funds. Karoly is a graduate of Eotvos University in Budapest, Hungary, and conducted postdoctoral studies at Tulane University in New Orleans and at the University of California San Francisco.
Richard Béliveau, Ph.D., Scientific Founder
Dr. Richard Béliveau obtained his Ph.D. in Biochemistry from Université Laval in 1980 and completed postdoctoral studies at Cornell University. He is full professor of biochemistry at Université du Québec à Montréal (UQAM) since 1984. Dr. Béliveau is an associate Professor of Surgery and of Physiology at the Université de Montréal, and is a member of the Group of Experimental Therapy of Cancer at the Oncology Department of the Jewish General Hospital. He also holds the Claude Bertrand Chair of Neurosurgery at the Centre Hospitalier of Université de Montreal. Since 1996, he has been the Director of the Laboratory of Molecular Medicine at UQAM and holds the Chair in the Prevention and Treatment of Cancer. He is the Head of a research team composed of over 25 researchers at UQAM, and he has authored 250 articles and 300 communications.
Quentin Smith, PhD
Dr. Smith is currently a Professor and Senior Associate Dean for Sciences at Texas Tech University. Dr. Smith holds a Bachelor's degree in Chemistry from Oberlin College and a Ph.D. in Pharmacology from the University of Utah. He worked for 17 years at the National Institutes of Health attaining the rank of Section Chief in the National Institute on Aging. He transferred to Texas Tech in 1997 to help build the new School of Pharmacy. His primary research interests are in the structure and function of the blood-brain barrier as well as in drug development and delivery to the central nervous system for the treatment of brain tumors and ischemic disease. He is the author of over 100 peer-reviewed research papers, and is a Fellow of the American Association of Pharmaceutical Scientists as well as a Grover E. Murray Professor. His research is funded by the National Institutes of Health and the Department of Defense Breast Cancer Research Program.
Steven L. Gonias, M.D., Ph.D.
Dr. Gonias received his B.S. in Biochemistry from the State University of New York at Stony Brook. He received his M.D. and Ph.D. degrees from Duke University, as a recipient of a scholarship from the Medical Scientist Training Program. After completing residency training in Anatomic and Clinical Pathology at Duke University and a post-doctoral research fellowship funded by a National Research Service Award, Dr. Gonias joined the faculty in the Departments of Pathology and Biochemistry and Molecular Biology at the University of Virginia. There, he developed a research program focusing on protease receptors and the cell-signaling pathways activated by these receptors. Dr. Gonias was named a Pew Scholar in the Biomedical Sciences. He held a number leadership positions in the UVa Cancer Center and served as Vice Chair for Research in the Pathology Department. In 2004, Dr. Gonias assumed the position of Chairperson of Pathology at the University of California San Diego. He continues an active research career and has now published over 180 peer-reviewed scientific papers.
Randy J. Seeley, Ph.D.
Dr. Randy Seeley is Professor of Medicine and holds the Donald C. Harrison Endowed Chair at the University of Cincinnati College of Medicine. In 2009, Dr. Seeley was appointed as the Director of the Cincinnati Diabetes and Obesity Center (CDOC). His scientific work has focused on the actions of various peripheral hormones in the CNS that serve to regulate food intake, body weight and the regulation of circulating fuels. In particular, he has focused upon the numerous hypothalamic and G.I. peptides and their associated receptors that influence both energy intake as well as peripheral metabolic processes with a focus on developing new treatment strategies for both obesity and diabetes.
Dr. Seeley received his B.A. from Grinnell College in 1989 and his Ph.D. from the University of Pennsylvania in 1993. He has published over 185 peer-reviewed articles and is the author of 14 book chapters. He is the recipient of the 2003 Lilly Scientific Achievement Award from the North American Association for the Study of Obesity and the co-recipient of the 2008 Ernst Oppenheimer award from the Endocrine society and is also the recipient of the 2009 Outstanding Scientific Achievement Award from the American Diabetes Association. Dr. Seeley has also served on numerous review panels for the NIH and currently serves on the NIDDK Clinical Obesity Research Panel.
Philippe Sarret, PhD
Philippe Sarret is an Associate Professor at the University of Sherbrooke. Recipient of a CIHR New Investigator award, he is the Co-Director of the Quebec Pain Research Network funded by the Fonds de la Recherche en Santé du Québec (FRSQ). He is also Director of the Neuroscience center at the University of Sherbrooke, which counts over 80 graduate students in clinical and basic research. Dr. Sarret is an awardee of the Canadian Pain Society Early Career Award for his important contribution to the understanding of the role of G-protein-coupled receptors in the underlying pain mechanisms. He is active as a pharmaceutical adviser and emphasizes translational research relevant to clinical applications. Since his recruitment in 2004, his work has been supported by various funding agencies (e.g., CIHR, FRSQ, NSERC, SRC) and industrial partners (Pfizer, Tranzyme Pharma, Angiochem). His team is currently composed of 15 M.Sc. and PhD students, 2 animal care technicians and 1 research assistant.
Patrick Y. Wen, MD
Dr. Wen is the Clinical Director of the Center for Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center and an Associate Professor of Neurology, Harvard Medical School. Dr. Wen graduated from the Medical College of St. Bartholomew's Hospital, University of London, in 1981. He completed his internal medicine training at the University of London postgraduate hospitals and his neurology residency in the Harvard-Longwood Neurology Training Program. His research is focused on novel treatments of brain tumors, especially targeted molecular agents. His other clinical interests include neurologic complications of cancer.